fomivirsen

(redirected from Vitravene)

fomivirsen

 [fo-miv´er-sin]
an antiviral agent administered by intravitreal injection in the treatment of cytomegalovirus retinitis associated with acquired immunodeficiency syndrome (AIDS); used as the sodium salt.

fomivirsen

/fo·mi·vir·sen/ (fo-miv´er-sin) an antiviral agent used as the sodium salt in the treatment of cytomegalovirusretinitis associated with AIDS.

fomivirsen

[fomiv′ersin]
an antiviral agent administered by intravitreal injection in the treatment of cytomegalovirus retinitis associated with acquired immunodeficiency syndrome (AIDS); used as the sodium salt.
References in periodicals archive ?
Seattle, RCC, TCC, CAP, WA and other Vitravene (fomivirsen) Isis Pharmaceuticals, CMV retinitis in Inc.
The company has commercialized its first product, Vitravene (fomivirsen), to treat CMV-induced retinitis in AIDS patients.
Reasons to buy This report will allow you to - - Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products, comprising Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and Neovasculgen.
The company has commercialized its first product, Vitravene (formivirsen), to treat CMV-induced retinitis in AIDS patients.
The company has already commercialized the first antisense drug in 1998 with Vitravene.
Reasons to buy "Gene Therapies A Diverse Range of Technologies with a Promising Long-Term Outlook" report includes : Understand the current status of the field of therapeutic gene therapies, and the relative clinical and commercial success of currently marketed products, comprising Glybera, Kynamro, Macugen, Vitravene, Gendicine, Oncorine, and Neovasculgen.
The company's first product, Vitravene, (fomivirsen), to treat CMV-induced retinitis in AIDS patients, is being sold in the United States, Europe, Brazil and Switzerland.
The company's first product, Vitravene (fomivirsen), to treat CMV-induced retinitis in AIDS patients, is being sold in the United States, Europe and Brazil.
Crooke and his colleagues founded Isis in 1989 and in 1998, succeeded in securing FDA approval for Vitravene, the world's first antisense drug.